GLENMARK PHARMACEUTICALS
|
The Current P/E Ratio of GLENMARK PHARMACEUTICALS is 55.70.
Share Price | ₹2,067.0 | Aug 01,2025 |
Market Cap | ₹58,329.3 Cr | |
Earnings-TTM | ₹1,047.1 Cr | TTM-Consolidated Results |
Price/Earnings | 55.70x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of GLENMARK PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹58,329.3 Cr] as on Aug 01,2025
(/) Earnings [ ₹1,047.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 55.70x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay 55.70 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLENMARK PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of GLENMARK PHARMACEUTICALS
PE Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 15.68x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 13.25x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2023 at 44.14x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does GLENMARK PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
GLENMARK PHARMACEUTICALS | 1,047.14 | 55.70 | 58,329.3 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 37.54 | 390,864.0 |
DIVIS LABORATORIES LTD | 2,191.00 | 77.05 | 168,811.0 |
CIPLA LTD | 5,406.81 | 22.43 | 121,260.0 |
TORRENT PHARMACEUTICALS LTD | 2,002.00 | 62.11 | 124,352.0 |
DR REDDYS LABORATORIES LTD | 5,726.70 | 17.77 | 101,786.0 |
MANKIND PHARMA LTD | 1,905.51 | 55.50 | 105,753.0 |
ZYDUS LIFESCIENCES LTD | 4,614.80 | 20.69 | 95,486.6 |
LUPIN LTD | 3,306.26 | 25.77 | 85,203.9 |
AUROBINDO PHARMA LTD | 3,515.26 | 17.84 | 62,709.1 |
ABBOTT INDIA LTD | 1,414.44 | 50.59 | 71,559.1 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLENMARK PHARMACEUTICALS 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 17.77x |
Max industry PE | 77.05x |
Median industry PE | 37.54x |
Average industry PE | 40.27x |
You may also like the below Video Courses